Blog

Clinical Development, Drug Development, Biotech, Pharma, Clinical Trials, FDA Weatherden Ltd Clinical Development, Drug Development, Biotech, Pharma, Clinical Trials, FDA Weatherden Ltd

Dose Matters: Navigating FDA Guidance for Oncology Drug Development 

For the last few years the FDA has been engaging with drug developers to reform how dose optimisation is approached for new cancer drugs. In August 2024 they finalised the eagerly-awaited guidance for industry. As part of our collaboration, Weatherden and Physiomics have worked together to help you understand and put this framework into action.

Read More
 
a 70c-.png

>200 companies

We have advised, worked with and supported dozens of funds and biotechs.

b 200m-.png

>500 million plus

Our input is benefitting patient populations worldwide.

c 13b-.png

>25 billion USD

Our repeat and long-term clients have realised significant value gains since we became involved in their programmes.